Ascelia Pharma (ACE.ST) Stock Analysis & AI Equity Report
Ascelia Pharma (ACE.ST) overview
Ascelia Pharma (ACE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Ascelia Pharma reported revenue of SEK 0m and operating profit of SEK -74.1m; the year-end share price was 3.22 SEK and market capitalisation was SEK 365m. Ascelia Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Ascelia Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-05-11. Data will be refreshed during report generation.
About Ascelia Pharma
Ascelia Pharma AB is a Swedish biotechnology company focused on orphan oncology treatments. It develops and commercializes drug candidates including Orviglance, an oral MRI contrast agent for detecting focal liver lesions in patients with impaired kidney function, and Oncoral, an oral irinotecan tablet in development for gastric cancer. The company is headquartered in Malmö and listed on Nasdaq Stockholm.
Generate the Ascelia Pharma report
Ascelia Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Ascelia Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.